BiotechTube

YHD1119 + Lyrica

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral Neuropathic Pain

Conditions

Peripheral Neuropathic Pain

Trial Timeline

Feb 7, 2017 → May 2, 2018

NCT ID
NCT02985216

About YHD1119 + Lyrica

YHD1119 + Lyrica is a phase 3 stage product being developed by Yuhan for Peripheral Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02985216. Target conditions include Peripheral Neuropathic Pain.

What happened to similar drugs?

20 of 20 similar drugs in Peripheral Neuropathic Pain were approved

Approved (20) Terminated (4) Active (0)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved
✅Ticagrelor + clopidogrelAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02985216Phase 3Completed
NCT02783183Phase 1Completed
NCT02783638Phase 1Completed

Competing Products

20 competing products in Peripheral Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
18
LY3857210 + PlaceboEli LillyPhase 2
35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
35
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Valemetostat TosylateDaiichi SankyoPhase 2
39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QutenzaAstellas PharmaPre-clinical
26
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
43
Qutenza exposureAstellas PharmaPre-clinical
26
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
Capsaicin 8% + PlaceboAstellas PharmaPhase 3
40